Rifapentine Cas:61379-65-5

We are Rifapentine CAS:61379-65-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Description:

Product Name: Rifapentine CAS NO: 61379-65-5  

                    

Synonyms:

rifamycin-S;

Rifamycin-B-tripropyl-hydrazid;

 

Chemical & Physical Properties:

Appearance: Red-brown crystalline powder

Assay :≥99.0%

Density: 1.35 g/cm3 (20℃)

Melting Point: 179-180℃

Boiling Point: 969.3±65.0℃(Predicted)

Refractive Index: 1.63

Storage Condition: Store in original container in a cool dark place.

Storage Temp.: -20℃ Freezer

Solubility: Methanol: soluble2mg/mL, clear, red to red-brown

 

Safety Information:

HS Code: 2941903000

Hazard Code: Xi

Risk Statements: R36/37/38

Safety Statement: S26

WGK Germany: 3

RTECS: JQ0902000

Toxicity: LD50 in mice (mg/kg): >2000 orally; 750 i.p. (Cricchio); LD50 in mice (mg/kg): 3300 orally; 710 i.p. (Aroli)

Symbol: GHS07

Signal Word: Warning

Hazard Statements: H315-H319-H335

Precautionary Statements: P261-P305 + P351 + P338

 

Rifapentine is a broad spectrum antibiotic highly active against Gram-positive bacteria and Neisseria gonorrhoea. It is reported to be 10 times more active than the structurally related rifampicin against Mycobacrerim fuberculosis. Unlike rifampicin the bioavailability of rifapentine is significantly increased when administered after a meal.

Rifapentine (Priftin; DL 473) is an antibiotic compound used in the treatment of tuberculosis.Target: AntibacterialRifapentine inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. A review of alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self -administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity . However the rates of treatment-limiting adverse events were higher in the rifapentine-isoniazid regimen.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Related Products:2,4-dihydroxy-3-(1-oxidaneyl)-13,23,33,43,61-hexaoxidan-1-one manufacturer | zinc hydrogen arsenate * H2O supplier | 2H-1-Benzopyran-2-thione,8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-7-propoxy-, hydrochloride producer.